Arbutus Biopharma Corp (ABUS) Net margin 2016–2025
Arbutus Biopharma Corp (ABUS) net profit margin by fiscal year — reported net income divided by reported revenue.
-237.9%FY2025 · since FY2016: -25765.5% → -237.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -237.9% | +895.2 pp |
| FY2024 | -1133.0% | -731.5 pp |
| FY2023 | -401.6% | -223.6 pp |
| FY2022 | -178.0% | +515.9 pp |
| FY2021 | -693.9% | +228.1 pp |
| FY2020 | -922.0% | +1635.4 pp |
| FY2019 | -2557.4% | -1597.6 pp |
| FY2018 | -959.8% | -170.9 pp |
| FY2017 | -788.9% | +24976.6 pp |
| FY2016 | -25765.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABUS financial trends
ABUS RevenueABUS Net incomeABUS Gross profitABUS Gross marginABUS Operating incomeABUS Operating marginABUS Operating cash flowABUS Free cash flowABUS Capital expendituresABUS Return on equityABUS Stock buybacksABUS Dividends paidABUS Total assetsABUS Total liabilitiesABUS Shareholders’ equityABUS overview →